Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Priming Immunotherapy in Advanced Disease With Radiation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03313804
Recruitment Status : Recruiting
First Posted : October 18, 2017
Last Update Posted : October 26, 2018
Sponsor:
Information provided by (Responsible Party):
John L. Villano, MD, PhD, University of Kentucky

Brief Summary:

This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint inhibitor (such as Nivolumab, Atezolizumab or Pembrolizumab) for disease treatment as per FDA approved guidelines. In these patients we will deliver a short-course radiation to a single systemic (non-CNS) site within 14 days of receiving the first dose of immune checkpoint inhibitors. This sequence allows radiation to release tumor antigens from immune inaccessible areas such as necrotic tumor or low perfusion to provide a robust anti-tumor immune response with immune checkpoint inhibitors.

The primary objective is to assess six-month progression free survival (PFS) compared to historical control.


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Drug: Immune checkpoint inhibitor Radiation: Radiation Therapy Phase 2

Detailed Description:

Subjects with front-line or relapsed NSCLC or relapsed HNSCC who are intended to receive standard of care immune checkpoint inhibitors without a contraindication to Stereotactic Body Radiation Therapy (SBRT) to a single cancer deposit greater than 1 cm (metastasis or primary cancer) will be enrolled. Subjects will receive standard of care (SOC) immune checkpoint inhibitors and within 2 weeks of initiation, and will receive either:

  • SBRT to target to achieve Biological Equivalent Dose (BED) > 100 Gy OR
  • 30 Gy fractionated radiation therapy (RT) delivered as a 3 dimensional (3-D) dose.

The lesion choice will be made by the treating radiation oncologist and will be directed to a single malignant focus (non-CNS) that measures ≥ 1 cm. Essentially, the goals of both techniques are the same but SBRT is reserved for lesions that are readily encompassed by a single field with large RT fractions in which dose-limiting organs are within safe limits.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Priming Immunotherapy in Advanced Disease With Radiation
Actual Study Start Date : October 26, 2017
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 30, 2028

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Immune Checkpoint Inhibitor + Radiation
Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
Drug: Immune checkpoint inhibitor
Standard of care immune checkpoint inhibitor

Radiation: Radiation Therapy
Stereotactic Body Radiation Therapy OR Fractionated radiation therapy




Primary Outcome Measures :
  1. The primary study endpoint is 6-month progression-free survival. [ Time Frame: 6-months post enrollment ]
    Progression-free survival will be calculated as time from enrollment in the study to progression at 6-months post enrollment.


Secondary Outcome Measures :
  1. Percentage of (programmed death) PD-1+ CD4+ T (helper) cells and PD-1+ CD8+ T (cytotoxic) cells prior to treatment versus with concurrent treatment. [ Time Frame: Assessed at specified points--1) prior to each cycle of therapy for 4 cycles (one cycle equals 6 weeks) 2) at disease progression (date first progression post-randomization, assessed up to 3 years) 3) when participant is off-study, assessed up to 3 years ]
  2. Percentage of CD8+ T-cells that are gamma-interferon positive during treatment. [ Time Frame: Assessed at specified points--1) prior to each cycle of therapy for 4 cycles (one cycle equals 6 weeks) 2) at disease progression (date first progression post-randomization, assessed up to 3 years) 3) when participant is off-study, assessed up to 3 years ]
  3. Percentage PD-L1+ CD4+ and PD-L1+ CD8+ T-cell expression differences during treatment [ Time Frame: Assessed at specified points--1) prior to each cycle of therapy for 4 cycles (one cycle equals 6 weeks) 2) at disease progression (date first progression post-randomization, assessed up to 3 years) 3) when participant is off-study, assessed up to 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically proven advanced or metastatic non-small cell lung cancer or squamous cell carcinoma head and neck with tumor at least 1 cm in size.
  2. Eligible for treatment with radiation therapy.
  3. Prior treatment: chemotherapy or radiotherapy or surgery.

    1. Prior chemotherapy or radiation must have concluded ≥ 21 days prior to the start of study treatment.
    2. No limit is placed on prior systemic treatment, but subjects must be eligible for immune checkpoint inhibitors therapy, for an FDA approved indication.
    3. No major surgery within 14 days of start of study treatment.
  4. No previous or concurrent malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for the past 3 years.
  5. Age ≥ 18 years.
  6. Life expectancy ≥ 3 months.
  7. Required initial laboratory values:

    1. Absolute neutrophil count ≥ 1,000/mm3
    2. Platelets ≥ 100,000/mm3
    3. Total bilirubin ≤ 1.5 x ULN
    4. AST and ALT if no hepatic metastasis ≤ 2.5 times x ULN
    5. AST and ALT with hepatic metastasis ≤ 5 x ULN
    6. Creatinine ≤ 1.5 x ULN and Requires CrCl ≥ 60ml/min (per 24-hour urine collection or calculated according to the Cockcroft-Gault formula)
  8. Non pregnant and non-nursing women. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Subjects should use adequate birth control for at least 3 months after the last administration of immune checkpoint inhibitors.
  9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Active clinically serious infection > CTCAE Grade 2.
  2. Serious non-healing wound, ulcer or bone fracture.
  3. Prior treatment with immune checkpoint inhibitors.
  4. Ineligible for immune checkpoint inhibitors based on package insert of the chosen immune checkpoint inhibitor (e.g., uncontrolled immunologic disorders, active hepatitis, active colitis, active pneumonitis, uncontrolled/active hormone gland problems - including thyroid, pituitary, adrenal glands and pancreas).
  5. Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration or those patients who receive a non-CNS minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration. There is no waiting period for central line placement. There is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain.
  6. Participants may not have uncontrolled inter-current illness. This includes, but is not limited to: ongoing or active infection; symptomatic congestive heart failure (NYHA class III or IV); unstable angina pectoris or new onset angina that began within the last 3 months; cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; or thrombotic/embolic events such as cerebrovascular accident, including transient ischemic attacks within the past 6 months. Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. Known Grade 3 or 4 neurotoxicity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03313804


Contacts
Layout table for location contacts
Contact: John Villano, MD, PhD 859-323-0405 jlvillano@uky.edu

Locations
Layout table for location information
United States, Kentucky
University of Kentucky Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: John Villano, MD, PhD    859-323-0405    jlvillano@uky.edu   
Sponsors and Collaborators
John L. Villano, MD, PhD
Investigators
Layout table for investigator information
Principal Investigator: John Villano, MD, PhD University of Kentucky

Layout table for additonal information
Responsible Party: John L. Villano, MD, PhD, Principal Investigator, University of Kentucky
ClinicalTrials.gov Identifier: NCT03313804     History of Changes
Other Study ID Numbers: MCC-17-MULTI-20-PMC
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Head and Neck Neoplasms